Waldenström Macroglobulinemia in the Very Elderly (≥75 years):Clinical Characteristics and Outcomes

Background: Patients with Waldenström Macroglobulinemia (WM) tend to present at an older age. Frailty, resulting from comorbidities and reduced organ function, poses unique challenges to the management of WM in the elderly. Age above 65 years, is an established unfavorable prognostic factor in WM. H...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2020-11, Vol.136 (Supplement 1), p.44-45
Main Authors: Zanwar, Saurabh, Abeykoon, Jithma P., Ansell, Stephen M., Gertz, Morie A., Paludo, Jonas, King, Rebecca L., He, Rong, Thompson, Carrie A., Warsame, Rahma M, Nowakowski, Grzegorz S., Inwards, David J., Witzig, Thomas E., Lacy, Martha Q., Gonsalves, Wilson I, Dispenzieri, Angela, Dingli, David, Go, Ronald S., Habermann, Thomas M., Kyle, Robert A., Rajkumar, S. Vincent, Kumar, Shaji K., Kapoor, Prashant
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Patients with Waldenström Macroglobulinemia (WM) tend to present at an older age. Frailty, resulting from comorbidities and reduced organ function, poses unique challenges to the management of WM in the elderly. Age above 65 years, is an established unfavorable prognostic factor in WM. However, data specifically pertaining to the very elderly patient population are scant. The impact of advanced age (≥75 years at diagnosis) on the clinical features and outcomes of patients with symptomatic/active WM were studied. Methods: Patients with active WM, evaluated at Mayo Clinic, Rochester between January 1996 and December 2018 were included in the study. The characteristics and laboratory parameters at presentation of the cohort of patients with the age ≥75 years were compared to those of the younger (age
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2020-142884